conivaptan has been researched along with amlodipine in 3 studies
| Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (amlodipine) | Trials (amlodipine) | Recent Studies (post-2010) (amlodipine) |
|---|---|---|---|---|---|
| 188 | 17 | 64 | 4,200 | 1,504 | 1,671 |
| Protein | Taxonomy | conivaptan (IC50) | amlodipine (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | 1.2 | |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | 0.4 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.602 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.8 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 2.898 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 5.521 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 2.7 | |
| Potassium channel subfamily K member 2 | Bos taurus (cattle) | 0.43 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for conivaptan and amlodipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for conivaptan and amlodipine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |